Boehringer Ingelheim, Anthem partner for largest real-world COPD trial
As part of a research collaboration launched in 2014, Boehringer Ingelheim and Anthem have partnered to study people with chronic obstructive pulmonary disease in real-world settings to assess how commonly-prescribed drugs may reduce the occurrence of COPD exacerbations. The team, which also includes Anthem’s outcomes research subsidiary HealthCore, plans to investigate whether adding an inhaled corticosteroid to a LAMA-LABA combination provides a meaningful benefit – a question under debate in the respiratory space. Get the full story at our sister site, Drug Delivery Business News. The post Boehringer Ingelheim, Anthem partner for largest real-world COPD trial appeared first on MassDevice.
CONCLUSIONS: This study provides detailed information that facilitates studying CRS and its main phenotypes. However, patient distribution of this study does not necessarily reflect disease distribution in the general population. PMID: 29911211 [PubMed - as supplied by publisher]
PMID: 29913496 [PubMed - in process]
PMID: 29916719 [PubMed - as supplied by publisher]
Conclusions CPA frequently developed in patients with MAC and M. kansasii PNTM. The treatment course of PNTM was not associated with all-cause mortality. However, systemic corticosteroid use and high CRP levels were negative prognostic factors of CPA in patients with PNTM. Since the prognosis is poor, early diagnosis and treatment of CPA are important in patients with PNTM.
Abstract Pulmonary diseases frequently involve imbalances in immunity. The inability to control bacteria in tuberculosis is a failed response to a pathogen. Idiopathic pulmonary fibrosis (IPF), a progressive fibrotic lung disease, can lead to respiratory failure and death within 3 years of diagnosis. Chronic obstructive pulmonary disease (COPD) progresses until death and in recent years has been labeled an autoimmune disease. Proposed mechanistic pathways of pathophysiology involve uncontrolled healing governed by pro-fibrotic cytokines that are unresponsive to the standard anti-inflammatory agents (e.g., cortic...
Although Th2 driven inflammation is present in COPD, it is not clearly elucidated which COPD patients are affected. Since periostin is associated with Th2 driven inflammation and inhaled corticosteroid (ICS)-r...
Conclusions: Our findings, albeit mostly descriptive and influenced by between-country differences, suggest that practice patterns differ between physician types, and the disease burden may be substantial for patients presenting in general practice.Int Arch Allergy Immunol
Condition: Chronic Obstructive Pulmonary Disease Interventions: Drug: SAR440340; Drug: Any Inhaled Corticosteroids as prescribed by treating physician as standard of care; Drug: Placebo; Drug: Any Long Acting Beta Agonist as prescribed by treating physician as standard of care; Drug: Any Long Acting Muscarinic Agonist as prescribed by treating physician as standard of care Sponsors: Sanofi; Regeneron Pharmaceuticals Not yet recruiting